0001551986-18-000017.txt : 20180828 0001551986-18-000017.hdr.sgml : 20180828 20180828163309 ACCESSION NUMBER: 0001551986-18-000017 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180824 FILED AS OF DATE: 20180828 DATE AS OF CHANGE: 20180828 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Almenoff June Sherie CENTRAL INDEX KEY: 0001492647 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37797 FILM NUMBER: 181041974 MAIL ADDRESS: STREET 1: C/O FURIEX PHARMACEUTICALS, INC. STREET 2: 3900 PARAMOUNT PARKWAY, SUITE 150 CITY: MORRISVILLE STATE: NC ZIP: 27560 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INNOVATE BIOPHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001551986 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8480 HONEYCUTT ROAD STREET 2: SUITE 120 CITY: RALEIGH STATE: NC ZIP: 27615 BUSINESS PHONE: 919-275-1933 MAIL ADDRESS: STREET 1: 8480 HONEYCUTT ROAD STREET 2: SUITE 120 CITY: RALEIGH STATE: NC ZIP: 27615 FORMER COMPANY: FORMER CONFORMED NAME: Monster Digital, Inc. DATE OF NAME CHANGE: 20150930 FORMER COMPANY: FORMER CONFORMED NAME: Tandon Digital, Inc. DATE OF NAME CHANGE: 20120611 4 1 wf-form4_153548837301387.xml FORM 4 X0306 4 2018-08-24 0 0001551986 INNOVATE BIOPHARMACEUTICALS, INC. INNT 0001492647 Almenoff June Sherie C/O INNOVATE BIOPHARMACEUTICALS, INC. 8480 HONEYCUTT ROAD, SUITE 120 RALEIGH NC 27615 0 1 0 0 COO and Chief Medical Officer Common stock 2018-08-24 4 P 0 100 4.85 A 100 I By Meadowlark Management LLC Common stock 2018-08-24 4 P 0 400 4.99 A 500 I By Meadowlark Management LLC Common stock 2018-08-27 4 P 0 47 4.90 A 547 I By Meadowlark Management LLC Common stock 2018-08-27 4 P 0 253 4.96 A 800 I By Meadowlark Management LLC Common stock 2018-08-27 4 P 0 100 4.94 A 900 I By Meadowlark Management LLC Common stock 2018-08-24 4 P 0 500 4.85 A 1400 I By Meadowlark Management LLC The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose. /s/ Kendyle Woodard, as Attorney-in-Fact 2018-08-28